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Abstract
Background There is limited information about the impact of coronavirus disease (COVID-19) on the muscular
dysfunction, despite the generalized weakness and fatigue that patients report after overcoming the acute phase of
the infection. This study aimed to detect impaired muscle efficiency by evaluating delta efficiency (DE) in patients with
COVID-19 compared with subjects with chronic obstructive pulmonary disease (COPD), ischaemic heart disease (IHD),
and control group (CG).
Methods A total of 60 participants were assigned to four experimental groups: COVID-19, COPD, IHD, and CG
(n = 15 each group). Incremental exercise tests in a cycle ergometer were performed to obtain peak oxygen uptake
(VO2peak). DE was obtained from the end of the first workload to the power output where the respiratory exchange
ratio was 1.
Results A lower DE was detected in patients with COVID-19 and COPD compared with those in CG (P ≤ 0.033).
However, no significant differences were observed among the experimental groups with diseases (P > 0.05). Lower
VO2peak, peak ventilation, peak power output, and total exercise time were observed in the groups with diseases than
in the CG (P < 0.05). A higher VO2, ventilation, and power output were detected in the CG compared with those in the
groups with diseases at the first and second ventilatory threshold (P < 0.05). A higher power output was detected in
the IHD group compared with those in the COVID-19 and COPD groups (P < 0.05) at the first and second ventilatory
thresholds and when the respiratory exchange ratio was 1. A significant correlation (P < 0.001) was found between the
VO2peak and DE and between the peak power output and DE (P < 0.001).
Conclusions Patients with COVID-19 showed marked mechanical inefficiency similar to that observed in COPD and
IHD patients. Patients with COVID-19 and COPD showed a significant decrease in power output compared to IHD
during pedalling despite having similar response in VO2 at each intensity. Resistance training should be considered
during the early phase of rehabilitation.
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Introduction
Coronavirus disease 2019 (COVID-19) is caused by severe
acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)
and was first identified in Wuhan, Hubei, China, in December
2019.1 The disease spread very rapidly to the rest of China and
later worldwide. A state of alarm was declared in Spain on 16
March 2020 with the aim of managing the emergency health
care situation produced by COVID-19. Up to 6 November
2020, a total of 1 328 832 confirmed cases and 38 883 deaths
by COVID-19 have been reported in Spain.2
As previously demonstrated by other coronaviruses,3
SARS-CoV-2 can infect different systems that share the same
ACE-2 receptors present in the respiratory system. Therefore,
most of the extrapulmonary manifestations occur in the
organs or systems with cells that express ACE-2 receptors
(heart, central nervous system, and muscle, among others).4
The inflammatory response induced in the airway by SARS-
CoV-2 can also lead to multisystemic inflammation that can
affect almost all organ systems, including the musculoskeletal
system.1,5 It has been described that the musculoskeletal sys-
tem is seriously burdened in patients with moderate to se-
vere SARS infection by causing significant skeletal muscle,
bone, joint, and neurological disorders.6,7 However, there is
limited information about the impact of COVID-19 on the
muscular system, despite the generalized weakness and
fatigue that patients report after overcoming the acute phase
of the infection.
Mechanical efficiency refers to the ability of an individual
to transfer energy consumed into external work. In other
words, poorer efficiency will increase the percentage of
maximal oxygen uptake (VO2max) required to sustain a given
mechanical work. Reduced mechanical efficiency indicates
that more energy is consumed at a given work output,
increasing the adenosine triphosphate (ATP) cost of
contraction (ATP consumed per work output).8
Several slightly varying indicators have been proposed for
the assessment of mechanical efficiency. Concretely, delta
efficiency (DE) is defined as the relationship between the
change in external work (ΔWext) and the change in total
energy expenditure (ΔEtot).
9 DE is considered a valid and
predictive parameter of the musculoskeletal efficiency in
cycling.9,10 This is also due, at least partly, to the fact that
the effect of various metabolic processes not contributing
to work performance is removed. In this regard, the work
of stabilizing muscles, and the work cost of respiratory
muscles,11 the movement cost of the lower limbs of the
body,12 and the basal metabolic rate,9 are not considered
during DE assessment. Thus, DE may be more effective for
understanding the efficiency of the musculoskeletal system.
The performance of patients with impaired muscle efficiency
decreases and, therefore, they may be limited in terms of
physical activity.13 Consequently, analysis of mechanical effi-
ciency could be valuable for the detection of muscle
dysfunction and the evaluation of any subsequent adaptation
in response to exercise.14
Taking into consideration that COVID-19 patients may
present an important muscle dysfunction, this study aimed
to detect impaired muscle efficiency by evaluating DE in
COVID-19 patients compared with subjects with chronic ob-
structive pulmonary disease (COPD), ischaemic heart disease
(IHD), and healthy controls.
Methods
This was a cross-sectional, observational study aiming to eval-
uate DE in COVID-19 patients. All patients provided informed
consent to participate in the study.
The Ethics and Research Committee of the Mataró Hospital
approved the study (Codi CEIm: 89/20). The protocol was
conducted in accordance with the principles of the Declara-
tion of Helsinki, Good Clinical Practice, and the applicable
and local regulatory requirements.
Participants
The study participants included adult patients who required
admission to the intensive care unit (ICU) for presenting re-
spiratory distress syndrome secondary to bilateral COVID-19
pneumonia. Healthy volunteers (control group) and individ-
uals with COPD or IHD were also recruited from existing data-
bases or the outpatient Cardiac and Pulmonary Rehabilitation
Unit of the Hospital de Mataró (Consorci Sanitiari del
Maresme) (n = 15 each experimental group).
The adjusted morbidity groups were obtained for all the
study participants. The adjusted morbidity group groups
morbidities according to data of patient diagnoses encoded
in the primary care and hospital medical care histories ad-
justed for the encoding date (acute or chronic processes).15,16
To be eligible, individuals with COPD had to have a
post-bronchodilator spirometry test showing a forced expira-
tory volume in the first second/forced vital capacity (FEV1/
FVC) <0.7 and FEV1 (% predicted) <70%. Individuals with
IHD had to have angiographic evidence of disease. Patients
with COPD or IHD had been clinically stable for 6 months,
without any deterioration in symptoms or episodes of angina
in IHD patients. Medications were taken as recommended by
the participants’ physicians during the study.
For COVID-19 patients, data related to admission were
collected, and the Acute Physiologic and Chronic Health
Evaluation (APACHE) II was determined as a predictive system
for disease severity and prognosis in patients in the ICU.17
The assessment of patients with COVID-19 was carried out
8 weeks after discharge from hospital.
The exclusion criteria for the four cohorts were severe
neurological disease, active oncological disease, joint
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problems preventing the cardiopulmonary exercise test
(CPET), or inability to understand or comprehend the guide-
lines for performing the CPET.
Cardiopulmonary exercise test
The CPET was performed on an electro-mechanically braked
bicycle ergometer (Ergoline900S, Ergoline GmbH, Bitz,
Germany). The cycling position, which is known to affect
energy expenditure, was standardized by adopting a top bar
position. Saddle height was adjusted according to the partic-
ipant’s leg length, and knee flexion was between 20° or 30°.
Toe-clips were used, and the participants were instructed to
stay seated during the test. The subjects were required to
maintain a constant pedal cadence between 50 and 70
revolutions per minute.
An individualized exercise protocol was performed in all
patients and was tailored to each patient’s physical condi-
tion, with gradual increments of 5, 10, 15, or 20 W·min1.
The required exercise time was between 6 and 12 min in or-
der to respect the proper kinetics of oxygen consumption
(VO2) and maintain a linear relationship between VO2,
exercise workload and heart rate during CPET. Throughout
the test, the patients were kept under continuous 12-lead
electrocardiographic-monitoring, and blood pressure was
established every 3 min.
VO2 was determined breath by breath using an automated
system (Ultima CardiO2, Medical Graphics Corporation, St.
Paul, MN, USA). Calibration was performed prior to each test
using standard gases of known oxygen and carbon dioxide
concentrations as well as a calibration syringe.
The first and second ventilatory thresholds (VT1 and VT2)
were determined following the method of ventilatory equiv-
alents (VE·VO2
1 and VE·VCO2
1) described by Skinner et al.18
VT1 corresponds to an increment of the VE·VO2
1 ratio with-
out an increased VE·VCO2
1 ratio, and with an increased con-
centration of oxygen fraction (PetO2). VT2 corresponds to an
increment of the VE·VCO2
1 ratio and a fractional decrease in
the concentration of CO2 (PetCO2).
Outcomes
Mechanical efficiency was calculated as the ratio of work ac-
complished per minute (Watts converted to kcal·min1) and
the energy expended per minute (kcal·min1). The conver-
sion factor 69.7 W·kcal1·min1 was used for estimation of
the work accomplished.19 An equation based on the thermal
equivalent of oxygen for the non-protein respiratory quotient
was used to estimate the energy expended20: Energy
expended (kcal·min1) = VO2·(1.2341·RER + 3.8124).
The mean values measured during the last 30 s of each
workload were considered for this estimation.19 Finally, DE
was calculated as the inverse of the slope in the linear
regression (y = ax + b), where y is the rate of expended en-
ergy (kcal·min1) and x is the rate of accomplished work
(kcal·min1).9 This value was obtained from the end of the
first workload, depending on the physical condition of the
participants, until the power output where the respiratory
exchange ratio (RER) was 1.19,21
Secondary outcomes included the total exercise time,
VO2peak (mL·kg
1·min1),VE (L·min1), peak power (W),
VO2 at VT1 (mL·kg
1·min1), VE at VT1 (L·min1), power
at VT1 (W), VO2 at VT2 (mL·kg
1·min1), VE at VT2 (L·min
1)
and power at VT2 (W).
Statistical analysis
The Shapiro–Wilk test was used to check the normal distribu-
tion of the data, which are reported as mean and standard
deviation (SD), mean, and confidence intervals (95% CI). To
compare the differences between the four experimental
groups (healthy control group, COVID-19, COPD, and IHD), a
univariate general linear model was applied. Bonferroni ad-
justment was used to identify multiple comparisons among
experimental groups.
The magnitude of the response to both experimental con-
ditions was estimated by partial eta-squared (ηp
2). The scale
for classification of ηp
2 was 0.10 = small, 0.25 = medium, and
0.40 = large.22 Statistical power was also calculated.
Total exercise time, VO2, VE, and power output during
CPET were compared by one-way analysis of variance
(ANOVA). When significant differences emerged, Bonferroni’s
post hoc was applied to establish differences between exper-
imental groups.
Significance was set at P < 0.05. All statistical procedures
were applied using the software package SPSS version 25.0
for Mac (SPSS Inc., Chicago, IL, USA).
Results
Patients
Table 1 describes the characteristics of the groups. Differ-
ences were observed in respiratory function tests among
the four study groups, except between the COVID-19 and
IHD groups (FVC, L, P = 0.361; FVC%, P = 0.840; FEV1, L,
P = 0.805; FEV1, %, P = 0.676; FEV1/FVC%, P = 0.086). Like-
wise, and given the study pathologies, we observed
statistically significant differences in morbidity among the
four study groups (Table 1). Table 2 describes the most rele-
vant clinical characteristics of the COVID-19 patients during
hospitalization.
Mechanical efficiency in COVID-19 patients 3
Journal of Cachexia, Sarcopenia and Muscle 2021
DOI: 10.1002/jcsm.12739
Delta efficiency
There were significant differences between experimental
groups in DE (F = 7.92; P < 0.001, ηp
2 = 0.30, SP = 0.99).
Bonferroni’s multiple comparisons showed a greater DE in
the healthy control group than in the COVID-19 and COPD
groups (P < 0.001 and P = 0.033, respectively). No significant
differences were found between the control group and the
IHD group (P = 0.052). No significant differences were
detected between the pathologies (P > 0.05) (Figure 1).
Secondary outcomes
To determine DE, VO2, and power output were obtained
where the RER was 1. VO2 and power output were lower in
patients with COVID-19 and COPD compared with the control
group (P < 0.01). Power output was higher in patients with
IHD compared with patients con COVID-19 and COPD
(P < 0.05). No significant differences were detected between
patients with COVID-19 and COPD in both variables
(P > 0.05). No significant differences were found between
patients with IHD and control group in both variables
(P > 0.05) (Figure 1).
The data corresponding to VO2, VE, power output, and to-
tal test time during CPET at VT1, VT2, and peak intensity are
presented in Table 3. VO2, VE, power output, and total exer-
cise time were lower in the three groups with diseases than
in the healthy group (P < 0.05) at VT1, VT2, and peak inten-
sities. When comparing the study groups with pathologies, a
higher peak power was found in IHD than in COPD patients
(P < 0.05). Power output was greater in the IHD than in the
COVID-19 and COPD groups (P < 0.05) at VT1 and VT2. No
other significant differences were detected among the
experimental groups (P > 0.05).
A significant correlation (r = 64, P < 0.001) was found be-
tween the VO2peak and DE and between the peak power out-
put and DE (r = 61, P < 0.001) (Figure 2). No other
correlations were detected (P > 0.05).
Discussion
To our knowledge, this is the first study to examine mechan-
ical efficiency during exercise in patients who have had
COVID-19 infection and required admission to the ICU due
to adult respiratory distress. The most relevant finding was
that patients with COVID-19 and COPD presented reduced
DE compared with healthy adult volunteers (control group).
It was noteworthy that DE did not change among the exper-
imental groups with cardiorespiratory diseases. Furthermore,
no differences were observed between patients with IHD and
the control group.
Other relevant findings showed a lower total exercise time,
VO2, VE (not at VT1), and power output in the three disease
groups compared with the control group after CPET. When
Table 1 Patients’ characteristics
HG COVIDG COPDG HDG P value
Age (years) 52.2 (4.9) 54.6 (9.1) 56.9 (7.1) 54.4 (8.5) 0.369
Men (%) 100 100 100 100 —
Body mass Index (kg/m2) 24.2 (3.5) 29.1 (4.4) 28.3 (6.51) 28.2 (4.0) 0.552
Adjusted morbidity groups (%) — — — — <0.001
Basal risk 100% 33.3% 0% 0% —
Low risk 0% 46.6% 13.3% 6.6% —
Moderate risk 0% 13.4% 53.3% 46.7% —
High risk 0% 6.7% 26.7% 46.7% —
Very high risk 0% 0% 6.7% 0% —
FVC (L) 5.1 (1.1) 3.8 (1.1) 2.7 (0.7) 4.1 (0.8) 0.007
FVC (%) 103.2 (15.8) 87.3 (17.1) 68.3 (15.2) 87.2 (9.7) 0.002
FEV1 (L) 3.9 (0.8) 3.1 (0.8) 1.4 (0.6) 3.2 (0.8) <0.001
FEV1 (%) 102.2 (17.7) 88.1 (24.1) 48.1 (21.1) 87.9 (15.1) <0.001
FEV1/FVC, % 79.9 (7.4) 82 (6.3) 53.3 (16.6) 77.2 (9.1) <0.001
COPDG, chronic obstructive pulmonary disease group; COVIDG, COVID-19 group; FEV1, forced expiratory volume in the first second; FVC,
forced vital capacity; HDG, heart disease group; HG, healthy group; SD, standard deviation.
Table 2 Patients’ characteristics COVID-19
ICU admission days* 11.6 (5.8)
Days of hospital admission* 23.2 (3.7)
Days mechanical ventilation* 10.1 (5.1)
Tracheostomy (no n, %) 100%
Prone positioning (yes, %) 86.6%
APACHE II* 11.6 (4)
Pa/Fi 24 h* post VM 168.4 (87.4)
D-dimer ICU admission* 673.6 (457.8)
PCR admission* 16.9 (12.4)
Lymphocytes admission* 687.3 (212.4)
Azithromycin (yes, %) 100%
Hydroxychloroquine (yes, %) 100%
Lopinavir (yes, %) 100%
Tocilizumab (yes, %) 53.3%
Interferon beta 1β (yes, %) 40%
Corticosteroid bolus (yes, %) 80%
APACHE, Acute Physiologic and Chronic Health Evaluation; ICU, in-
tensive care unit.
* Data are provided as mean and standard deviation (SD).
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the three pathologies were compared, the power output in
patients with COVID-19 and COPD was lower than that of
patients with IHD at intensities of VT1 and VT2 and when
the RER was 1.
Unfortunately, at present, the DE results of our study can-
not be reinforced by previous studies in patients with
COVID-19 and, furthermore, research comparing patients
with COPD and IHD are limited. The DE observed in patients
with COVID-19 (19.9%) were slightly lower (no significant)
than those obtained in patients with COPD and IHD (~23%),
and significantly lower compared to the control group
(~27%). Other studies have reported mean DE values of
~25–26% in patients with COPD and with heart failure with
reduced ejection fraction during submaximal cycling.23,24
Perrault et al. did not find significant differences between
patients with COPD (26.3%) and a control group (24.8%).25
According to a review article,26 the mean DE of 14 studies
was 23.8 ± 2.6%. Similar DE (23.8%) was reported in another
study with sport science students.27 Given the reported re-
sults in these studies, it appears that COVID-19 patients
may have decreased mechanical efficiency compared with
healthy people and about 20% could be a reference value
for DE. More studies with COVID-19 patients are needed to
corroborate such claims.
Several clinical sequelae should be considered to under-
stand a decrease in mechanical efficiency in patients with
COVID-19. Survivors of SARS-CoV-2 are highly prone to devel-
oping severe clinical respiratory, cardiovascular, and psycho-
social sequelae. These sequelae are linked to important
physical decline and significant fatigue.28 In addition, muscle
soreness, muscle fatigue, and weakness are stated symptoms
in COVID-19 patients.29
Similarly, patients with COPD also present symptoms asso-
ciated with impaired respiratory capacity,30 discomfort in the
legs and dysfunction of the peripheral muscles (muscle atro-
phy and weakness, fatigue) that limit exercise capacity.31–33
Given the significant muscle pain, fatigue, and weakness that
patients with COVID-19 present, it is plausible to propose a
poor mechanical efficiency in COVID-19 patients, which
may, in turn affect the exercise tolerance as in patients with
COPD occur.8
Several physiological mechanisms have been proposed to
explain deficiencies in mechanical efficiency associated with
the peripheral skeletal muscle. Leg discomfort and peripheral
muscle dysfunction could affect exercise tolerance by alter
muscle energy production during exercise and rest.8 This in-
crease is usually associated with a rise in the proportion of
Type II muscle fibres during exercise in patients with
COPD.34,35 This recruitment of Type II fibres is three to four
times greater than in Type I fibres.36
During CPET, different metabolic moments took place from
the start of exercise until the value of the RER was 1, and
thus, the recruitment pattern of motor units was likely mod-
ified from Type I to Types IIa and IIb as the work rate in-
creased and the fibres became progressively fatigued.37 The
similar behaviour observed between patients with COPD
and COVID-19 suggests that a premature recruitment of less
efficient Type II motor units occurred, leading to an increase
in energy cost during skeletal muscle contraction. The de-
creased oxidative capacity of Type II fibres,38 the attenuated
Figure 1 Comparisons in delta efficiency (A), VO2 when the RER was 1
(B), and peak power when the RER was 1 (C) between the experimental
groups. Abbreviations: CG, healthy control group; COPD, chronic obstruc-
tive pulmonary disease; DE, delta efficiency; IHD, ischaemic heart disease;
RER, respiratory exchange ratio; VO2, oxygen uptake.
a
Higher DE, VO2,
and peak power were detected in the healthy control group compared
with the COVID-19 and COPD groups (P < 0.05). (n = 15 each experimen-
tal group).
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activity of some enzymes involved in the Krebs cycle,39,40 and
the greater energy cost of muscle contraction induced an un-
usual ATP consumption and, consequently, a reduction in DE
in these patients,8 contributing to the early onset of muscle
fatigue. Inefficiency in humans is associated with a decrease
in mitochondrial efficiency.41 Probably, these biochemical
and physiological mechanisms were, at least partly, a key fac-
tor to detect a reduced DE in COVID-19 patients. In this study,
we did not analyse the increase in energy cost during muscle
contraction and its association with the recruitment of motor
units, and therefore, our arguments were based on the find-
ings of others.8,34–37 Unfortunately, the absence of muscle
biopsies is a methodological limitation for this study. More
research is warranted to clarify these arguments in patients
with COVID-19 disease.
As expected, functional capacity was significantly reduced
in patients with diseases compared with the control group.
Similar values of VO2peak have been observed in other
studies in patients with COPD (12.8 mL·kg1·min1,42
heart diseases (16–18 mL·kg1·min1)43 and COVID-19
(17.2 mL·kg1·min1).44 Interestingly, Carvalho-Jr et al. found
that patients with COPD who had lower FEV1 had lower
VO2peak.
42 They concluded that FEV1 was a predictor of
VO2peak to determine risk and severity in patients with COPD.
In our study, patients with COVID-19 presented a VO2peak
similar to that of patients with COPD and IHD, however,
FEV1 was much higher in patients with COVID-19 and IHD
compared with patients with COPD. The ventilatory response
at rest (spirometry) in patients with COVID-19 and IHD was
similar to that of the control group and higher compared
with those in patients with COPD; however, cardiorespiratory
response was impaired in all experimental groups with
diseases during CPET. Perhaps, FEV1 is not a differential factor
to predict VO2peak determining risk and severity in COVID-19
patients.
No differences were detected in VO2peak between the pa-
thologies while, conversely, variances were found in the
power output developed between the patients with
Table 3 Differences in total exercise time, VO2, VE, and power output at VT1 and VT2, and peak intensities between experimental groups
HG COVIDG COPDG IHDG P value
Total exercise
time (min:s)
11:20a (10:14–12:25) 8:14 (7:01–9:28) 7:22 (6:25–8:20) 9:04 (7:36–10:32) <0.001
VO2peak
(mL·kg1·min1)
32.31a (28.32–36.31) 17.30 (14.82–19.78) 14.35 (12.97–15.73) 18.82 (15.64–22) <0.001
VE (L·min1) 83.35a (67.33–99.36) 55.05 (45.94–64.15) 38.19 (33.11–43.28) 58.79c (49.09–68.50) <0.001
Peak power (W) 215.60a (181.84–249.37) 89.67 (69.74–109.60) 74.67 (62.79–86.54) 130.93c (102.25–159.62) <0.001
VO2 at VT1
(mL·kg1·min1)
14.40a (12.33–16.47) 8.94 (7.89–9.99) 9.25 (8.19–10.30) 10.58 (9.03–12.13) <0.001
VE at VT1 (L·min1) 24.75 (19.81–29.70) 21.42 (17.61–25.19) 21.57 (18.73–24.42) 24.54 (20.84–28.24) 0.394
Power at VT1 (W) 84.47a (68.74–100.19) 29.67 (17.51–41.83) 28.20 (15.39–41.01) 61.60b (45.73–77.47) <0.001
VO2 at VT2
(mL·kg1·min1)
25.18a (21.78–28.58) 12.80 (11.34–14.26) 12.14 (10.56–13.72) 14.83 (12.53–17.13) <0.001
VE at VT2 (L·min1) 53.21a (42.02–64.41) 35.81 (29.71–41.92) 29.92 (25.11–34.72) 39.08 (33.11–45.04) <0.001
Power at VT2 (W) 176.53a (147.48–205.58) 69.20 (52.53–85.87) 62.21 (49.36–75.04) 108.41b (87.11–129.69) <0.001
COPDG, chronic obstructive pulmonary disease group; COVIDG, COVID-19 group; HG, healthy group; IHDG, ischaemic heart disease
group; VE, minute ventilation; VO2, oxygen uptake; VT1, first ventilatory threshold; VT2, second ventilatory threshold.
Data are provided as mean and 95% confidence intervals (95% CIs).
aSignificantly different from COVIDG, COPDG, and IHDG (P < 0.05).
bSignificantly different from COVIDG and COPDG at VT1 and VT2 intensities (P < 0.05).
cSignificantly different from COPDG (P < 0.05).
Figure 2 Correlations between delta efficiency (DE) and peak oxygen up-
take (VO2peak) (r = 0.64, P < 0.001) (A); peak power output in watts (W)
(r = 0.61, P < 0.001) (B) (all participants, n = 60).
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respiratory diseases (COVID-19 and COPD) and IHD. Under
these premises, patients with IHD should probably have a
higher DE (ΔWext/ΔVO2) due to increased power output com-
pared with patients with COVID-19 and COPD. However, DE
remained unchanged among the experimental groups with
diseases, which represents a similar proportional raise in
the increase in power output and in VO2 from the end of
the first workload until where the respiratory exchange ratio
was 1. What seems evident is that patients with COVID-19
and COPD develop less force when pedalling during
incremental CPET.
To conclude this discussion, we would like to emphasize
the relationship between VO2peak and peak power and DE.
Several studies have demonstrated an inverse correlation
between DE, gross efficiency, and VO2max in world-class
cyclists.19,45 The participants with the highest DE and gross
efficiency had the lowest VO2max. The authors concluded
that a low VO2max could be offset by increased muscle effi-
ciency. This could be due to a physiological adaptation to
training that would allow world-class cyclists to continue at
a highly competitive level. However, we found a positive
correlation between DE and VO2peak and peak power in
the experimental groups. The participants with the highest
DE had the highest VO2peak and peak power. The partici-
pants in this study suffered from various diseases (except
the control group) and were not trained. This probably sug-
gests that the cardiorespiratory fitness and muscular fitness
of the lower extremities are a determining factor for improv-
ing mechanical efficiency. The physical condition of COVID-19
patients could be a key factor in achieving a faster recovery.
It would be interesting to propose a rehabilitation pro-
gramme to know the evolution of cardiorespiratory and
muscular fitness and mechanical efficiency in COVID-19
patients.
Conclusions
Patients with COVID-19 infection showed marked mechanical
inefficiency similar to that observed in patients with COPD
and IHD. The limiting factor was the muscle power developed
during pedalling, which showed muscle dysfunction in
patients with COVID-19 as a determining symptomatic factor.
Strength development programmes should be considered
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